BidaskClub lowered shares of BioLife Solutions (NASDAQ:BLFS) from a buy rating to a hold rating in a report issued on Saturday morning.
BLFS has been the subject of several other reports. Janney Montgomery Scott upgraded BioLife Solutions to a buy rating and set a $5.00 price target for the company in a report on Thursday, December 20th. B. Riley set a $22.00 price objective on BioLife Solutions and gave the stock a buy rating in a research report on Friday, November 9th. Finally, ValuEngine raised BioLife Solutions from a hold rating to a buy rating in a research report on Thursday, January 31st. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. BioLife Solutions presently has an average rating of Buy and an average target price of $17.75.
Shares of BioLife Solutions stock opened at $16.74 on Friday. BioLife Solutions has a 1 year low of $4.85 and a 1 year high of $26.35. The stock has a market capitalization of $302.29 million, a price-to-earnings ratio of -79.71 and a beta of 1.49.
A number of hedge funds and other institutional investors have recently modified their holdings of BLFS. Canton Hathaway LLC acquired a new position in BioLife Solutions during the fourth quarter valued at approximately $66,000. GSA Capital Partners LLP boosted its position in BioLife Solutions by 21.1% during the fourth quarter. GSA Capital Partners LLP now owns 13,800 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 2,400 shares during the last quarter. Northern Trust Corp boosted its position in BioLife Solutions by 24.4% during the second quarter. Northern Trust Corp now owns 16,304 shares of the medical equipment provider’s stock valued at $186,000 after purchasing an additional 3,200 shares during the last quarter. Weiss Multi Strategy Advisers LLC acquired a new position in BioLife Solutions during the fourth quarter valued at approximately $241,000. Finally, Janney Montgomery Scott LLC boosted its position in BioLife Solutions by 7.3% during the fourth quarter. Janney Montgomery Scott LLC now owns 20,515 shares of the medical equipment provider’s stock valued at $247,000 after purchasing an additional 1,400 shares during the last quarter. 42.09% of the stock is owned by hedge funds and other institutional investors.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.